Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-day dose-ranging study of GSK961081 in moderate to severe COPD
NL-OMON36391Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of batefenterol in chronic obstructive pulmonary disease (COPD) (8 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough FEV1 on Day 29. Started Feb 2011; status: active, not recruiting.
02
Drugs
batefenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON36391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36391.